Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ABOS Stock Forecast 2026-2027
$2.34
Current Price
$169.01M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ABOS Price Targets
+327.4%
To High Target of $10.00
+241.9%
To Median Target of $8.00
+70.9%
To Low Target of $4.00
ABOS Price Momentum
+6.8%
1 Week Change
+2.6%
1 Month Change
+105.3%
1 Year Change
+10.9%
Year-to-Date Change
-35.0%
From 52W High of $3.60
+122.9%
From 52W Low of $1.05
📊 TOP ANALYST CALLS
Did ABOS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Acumen is one of their latest high-conviction picks.
Latest ABOS Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, ABOS has a bullish consensus with a median price target of $8.00 (ranging from $4.00 to $10.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $2.34, the median forecast implies a 241.9% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ABOS Analyst Ratings
6
Buy
0
Hold
0
Sell
ABOS Price Target Range
Low
$4.00
Average
$8.00
High
$10.00
Current: $2.34
Latest ABOS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ABOS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 26, 2026 | BTIG | Thomas Shrader | Buy | Reiterates | $8.00 |
| Mar 16, 2026 | BTIG | Buy | Maintains | $N/A | |
| Jan 27, 2026 | BTIG | Buy | Maintains | $N/A | |
| Nov 18, 2025 | B of A Securities | Buy | Maintains | $N/A | |
| Aug 25, 2025 | B of A Securities | Buy | Maintains | $N/A | |
| Jun 17, 2025 | Citigroup | Buy | Initiates | $N/A | |
| Mar 28, 2025 | UBS | Buy | Maintains | $N/A | |
| Mar 28, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 13, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 3, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 15, 2024 | UBS | Buy | Maintains | $N/A | |
| Aug 14, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 25, 2024 | Citigroup | Buy | Initiates | $N/A | |
| May 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 31, 2024 | UBS | Buy | Maintains | $N/A | |
| Mar 27, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Dec 12, 2023 | Deutsche Bank | Buy | Initiates | $N/A | |
| Aug 9, 2023 | Credit Suisse | Outperform | Reiterates | $N/A | |
| Aug 9, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 17, 2023 | Cantor Fitzgerald | Overweight | Reiterates | $N/A |
Acumen Pharmaceuticals, Inc. (ABOS) Competitors
The following stocks are similar to Acumen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Acumen Pharmaceuticals, Inc. (ABOS) Financial Data
Acumen Pharmaceuticals, Inc. has a market capitalization of $169.01M with a P/E ratio of -1.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -93.2%.
Valuation Metrics
Market Cap
$169.01M
Enterprise Value
$71.78M
P/E Ratio
-1.2x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+76.0%
Current Ratio
4.6x
Debt/Equity
35.6x
ROE
-93.2%
ROA
-42.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Acumen Pharmaceuticals, Inc. (ABOS) Business Model
About Acumen Pharmaceuticals, Inc.
What They Do
Develops targeted therapies for Alzheimer’s disease.
Business Model
Acumen Pharmaceuticals operates as a clinical-stage biopharmaceutical company, focusing on developing and advancing therapies that modify the progression of Alzheimer’s disease. The company generates potential revenue through the development of its lead drug candidate, ACU193, which targets amyloid-beta oligomers, and seeks to monetize through partnerships, licensing agreements, and eventual sales upon successful clinical trials and regulatory approvals.
Additional Information
Founded in 1996 and headquartered in Newton, Massachusetts, Acumen Pharmaceuticals is addressing a critical unmet medical need in the neuroscience sector. Its key clinical programs, ALTITUDE-AD and INTERCEPT-AD, are designed to assess the efficacy and safety of ACU193, with implications for cognitive improvement in Alzheimer’s patients.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
60
CEO
Mr. Daniel J. O'Connell M.B.A.
Country
United States
IPO Year
2021
Website
acumenpharm.comAcumen Pharmaceuticals, Inc. (ABOS) Latest News & Analysis
Latest News
Quick Summary
Acumen Pharmaceuticals focuses on Alzheimer's treatment sabirnetug, with key 2026 Phase 2 results expected from the ALTITUDE-AD trial, which may impact future Phase 3 development.
Why It Matters
Acumen's Phase 2 readout for sabirnetug in 2026 could significantly impact its valuation. Positive data may attract investment and position the company favorably for Phase 3 trials.
Source: Seeking Alpha
Market Sentiment:
Neutral
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
1 month ago
Quick Summary
Acumen Pharmaceuticals, Inc. (ABOS) presented at the Bank of America Global Healthcare Conference, highlighting key developments and insights relevant to investors.
Why It Matters
Acumen Pharmaceuticals' presentation at a major healthcare conference may signal new developments or insights, potentially impacting stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Acumen Pharmaceuticals (NASDAQ: ABOS) reports that its Phase 2 ALTITUDE-AD trial for sabirnetug is on schedule, with top-line results anticipated in late 2026.
Why It Matters
Acumen Pharmaceuticals' trial progress and upcoming results could significantly impact its stock value and investor sentiment in the Alzheimer's drug market, influencing future funding and partnerships.
Source: MarketBeat
Market Sentiment:
Neutral
Quick Summary
Acumen Pharmaceuticals, Inc. (ABOS) held its Q1 2026 earnings call, discussing financial performance and company developments. Further details can be found in the full transcript.
Why It Matters
Acumen Pharmaceuticals' Q1 2026 earnings report provides insights into financial performance, growth potential, and strategic direction, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
1 month ago
Quick Summary
Acumen Pharmaceuticals (NASDAQ: ABOS) reported Q1 2026 financial results and provided a business update, focusing on its Alzheimer's disease treatments targeting amyloid beta oligomers.
Why It Matters
Acumen Pharmaceuticals' financial results and updates on Alzheimer's drug development can influence stock performance and investor confidence in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Acumen Pharmaceuticals (NASDAQ: ABOS) will report its Q1 financial results on May 12, 2026. The company focuses on therapies for Alzheimer's disease targeting amyloid beta oligomers.
Why It Matters
Acumen Pharmaceuticals' upcoming financial results may influence stock performance, reflecting investor sentiment on its Alzheimer's drug development progress and potential market impact.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ABOS Stock
What is Acumen Pharmaceuticals, Inc.'s (ABOS) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Acumen Pharmaceuticals, Inc. (ABOS) has a median price target of $8.00. The highest price target is $10.00 and the lowest is $4.00.
Is ABOS stock a good investment in 2026?
According to current analyst ratings, ABOS has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.34. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ABOS stock?
Wall Street analysts predict ABOS stock could reach $8.00 in the next 12 months. This represents a 241.9% increase from the current price of $2.34. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Acumen Pharmaceuticals, Inc.'s business model?
Acumen Pharmaceuticals operates as a clinical-stage biopharmaceutical company, focusing on developing and advancing therapies that modify the progression of Alzheimer’s disease. The company generates potential revenue through the development of its lead drug candidate, ACU193, which targets amyloid-beta oligomers, and seeks to monetize through partnerships, licensing agreements, and eventual sales upon successful clinical trials and regulatory approvals.
What is the highest forecasted price for ABOS Acumen Pharmaceuticals, Inc.?
The highest price target for ABOS is $10.00 from at , which represents a 327.4% increase from the current price of $2.34.
What is the lowest forecasted price for ABOS Acumen Pharmaceuticals, Inc.?
The lowest price target for ABOS is $4.00 from at , which represents a 70.9% increase from the current price of $2.34.
What is the overall ABOS consensus from analysts for Acumen Pharmaceuticals, Inc.?
The overall analyst consensus for ABOS is bullish. Out of 2 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are ABOS stock price projections?
Stock price projections, including those for Acumen Pharmaceuticals, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 9:39 AM UTC